Published in final edited form as:

Stroke. 2014 November ; 45(11): 3320–3324. doi:10.1161/STROKEAHA.114.006228.

Complication Rates and Center Enrollment Volume in the Carotid Revascularization Endarterectomy versus Stenting Trial

Nicole R. Gonzales, M.D.¹, Bart M. Demaerschalk, M.D.², Jenifer H. Voeks, Ph.D.³, MeeLee Tom, MS⁴, George Howard, DrPH⁵, Alice J. Sheffet, PhD⁴, Lawrence Garcia, M.D.⁶, Daniel G. Clair, M.D.⁷, John Barr, M.D.⁸, Steven Orlow, M.D.⁹, and Thomas G. Brott, M.D.^{4,10} on behalf of the CREST Investigators

¹Department of Neurology, University of Texas Science Health Center, Houston, TX

²Department of Neurology, Mayo Clinic, Scottsdale, AZ

³Department of Neurosciences, Medical University of South Carolina, MUSC Stroke Center, Charleston, SC

⁴Department of Surgery, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ

⁵Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

⁶Interventional Cardiology, Steward St. Elizabeth's Medical Center, Boston, MA

⁷Department of Vascular Surgery, Cleveland Clinic, Cleveland, OH

⁸Departments of Radiology and Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX

⁹Department of Cardiology, Northern Indiana Research Alliance, Lutheran Hospital of Indiana, Ft. Wayne, IN

¹⁰Department of Neurology, Mayo Clinic, Jacksonville, FL

Abstract

Background and Purpose—Evidence indicates that center volume of cases affects outcomes for both carotid endarterectomy (CEA) and stenting (CAS). We evaluated the effect of enrollment

Corresponding author: Thomas G. Brott, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA, Brott.Thomas@mayo.edu, 904-953-0556 (T), 904-953-0277 (F).

All those who meaningfully contributed to the manuscript are listed as an author.

CONFLICT OF INTEREST DISCLOSURE

N. R. Gonzales - None

B. M. Demaerschalk - None

J. H. Voeks - None

M. Tom - None

G. Howard - None

L. Garcia - None

D. Clair – Consultant: Arsenal Medical, Confluent, Endologix, Vessix Vascular, Volcano Corp.; DSMB member: Bard; Advisory Board: Boston Scientific, Medtronic

J. Barr – Shareholder: Boston Scientific, Medtronic; Consultant: Covidien

S. Orlow - None

T. G. Brott - None

volume by site on complication rates in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST).

Methods—The primary composite endpoint was any stroke, myocardial infarction, or death within 30 days or ipsilateral stroke in follow-up. The 477 approved surgeons performed >12 procedures per year with complication rates <3% for asymptomatic patients and <5% for symptomatic patients; 224 interventionists were certified after a rigorous two step credentialing process. CREST centers were divided into tertiles based on the number of patients enrolled into the study, with Group 1 sites enrolling <25 patients, Group 2 sites enrolling 25–51 patients and Group 3 sites enrolling >51 patients. Differences in periprocedural event rates for the primary composite endpoint and its components were compared using logistic regression adjusting for age, sex, and symptomatic status within site-volume level.

Results—The safety of CAS and CEA did not vary by site-volume during the periprocedural period as indicated by occurrence of the primary endpoint ($p=0.54$) or by stroke and death ($p=0.87$). A trend towards an inverse relationship between center enrollment volume and complications was mitigated by adjustment for known risk factors.

Conclusions—Complication rates were low in CREST and were not associated with center enrollment volume. The data are consistent with the value of rigorous training and credentialing in trials evaluating endovascular devices and surgical procedures.

Keywords

Carotid stenting; carotid endarterectomy; enrollment volume; complication rates; training; randomized clinical trial; stroke

INTRODUCTION

Carotid endarterectomy (CEA) and carotid angioplasty and stenting (CAS) are technically demanding procedures associated with learning curves. For CEA, there is evidence that both surgeons' cumulative experience and intensity of experience may contribute to successfully achieving satisfactorily low morbidity and mortality indices.^{1–3} Although the study was conducted during a period with higher periprocedural stroke and death rates from CEA, a combined perioperative mortality and neurologic morbidity <3% was not reached until after performance of >50 CEA operations per year and a cumulative experience of >325 CEA total.¹ Existing literature suggests that it may be difficult to separate the effect of the intensity and the cumulative nature of the operative experience, but both are important.¹ Studies also suggest that the effect of a learning curve related both to technical expertise and patient selection may influence the outcomes of CAS.⁴ CAS operator volume to establish experience with CAS may be only one important factor in avoidance of complications. CAS complication rates may also be related to collective institutional proficiency and experience encompassing factors such as patient selection, device selection, and adjunctive medical management, along with reviews of lessons learnt from collegial reviews of all cases.⁵

Systematic review and meta-analysis data from primary studies on center volume to outcome relationships in CEA revealed that significantly lower mortality and stroke rates were achieved at hospitals providing a higher annual hospital volume of CEA.⁶ Likewise,

important determinants of CAS outcomes include both site and operator CAS volume.⁷ In addition, for CAS, results demonstrated a reduction of in-hospital stroke rates associated with increasing center experience^{8,9} Lastly, annual CAS procedure in-trial volume has also been associated with outcome.¹⁰ We sought to evaluate the effect of enrollment by site on complication rates in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). We hypothesized there would be improved performance with increasing enrollment volume.

METHODS

Study Design

The study design and primary results of CREST have been previously reported.^{11, 12} CREST is a prospective, multi-centered, randomized clinical trial with blinded endpoint adjudication comparing the efficacy of CEA and CAS in preventing stroke, myocardial infarction, and death during a 30-day periprocedural period, and stroke ipsilateral to the study artery over the follow-up period in patients with symptomatic or asymptomatic carotid stenosis. The protocol was approved by the institutional/ethics review boards at all participating sites and all participants provided signed informed consent. Patients were enrolled between December 2000 and July 2008 at 117 clinical centers in the United States and Canada. Participants who had a stroke or TIA in the distribution of the study artery within 180 days before randomization were considered symptomatic and eligible if they had ipsilateral stenosis of 50% by angiography, 70% by ultrasound, or 70% by computed tomographic angiography (CTA) or magnetic resonance angiography (MRA) if ultrasound was 50–69%. Patients who had not had a stroke or TIA associated with the study artery within the previous 180 days were considered asymptomatic and eligible if the ipsilateral stenosis was 60% by angiography, 70% by ultrasound, or 80% by CTA or MRA if ultrasound was 50–69%. Complete inclusion and exclusion criteria have been published elsewhere.^{11, 12}

Interventionalist and Surgeon Certification

Patients could not be randomly assigned to a treatment group until the interventionalists performing CAS and surgeons performing CEA had been certified. The details of certification have been previously described.^{11–14} The Interventional Management committee (IMC), consisting of a multi-disciplinary group of physicians, was responsible for the rigorous two-step credentialing process of the interventionalists applying for CREST. Candidates were required to submit case studies of up to 30 previous CAS cases, and selection of interventionalists was based on the demonstration of mandatory clinical and technical skills. After approval to join CREST and before enrolling patients in the lead-in phase, interventionalists without previous experience with the study devices were required to participate in a specially designed Carotid Stent Operator Certification Program (CSOCP). The CSOCP was an intensive didactic program consisting of an overview of the CREST protocol, with strong emphasis on carotid stenting. Training included diagnostic angiography, complex anatomy, post-procedure care and management of carotid complexities. The participants were in-serviced on the trial devices and given the opportunity to work with bench models. There was at least one live case observation utilizing the trial devices.

For surgeons, the Surgical Management Committee (SMC) used approaches proven successful in the Asymptomatic Carotid Atherosclerosis Study (ACAS)¹⁵ where candidates submitted approximately 50 CEA procedures for review prior to approval for participation in the trial.¹⁶ Criteria for approval included performance of greater than 12 CEA procedures per year with complication rates less than 3% for asymptomatic patients and less than 5% for symptomatic patients.

There was ongoing monitoring of complications in CREST. Per protocol, the Statistical and Data Management Center informed the CREST Principal Investigator and the SMC or IMC the first time a stroke or death occurred at a clinical site, which initiated a “watch” status. A second death or stroke triggered a potential audit of the site and the individual operator by the appropriate committee. A site visit or additional proctoring might be required. According to the severity and number of events, an individual operator or clinical site could be terminated from participating in the trial. An independent DSMB appointed by the NIH met about twice yearly for additional oversight of the study. There were no operators with more than 2 events. No sites, surgeons, or interventionalists were withdrawn because of untoward complications.

Treatment

Participants were randomly assigned to receive either CAS or CEA. Patients randomized to CAS were treated with aspirin and clopidogrel 48 hours before and for 30 days after the procedure. Patients were treated with the RX ACCULINK stent, and whenever feasible, the RX ACCUNET embolic-protection device. Patients randomized to CEA received aspirin at least 48 hours prior and continued for a year or more. Full details of the protocol have been reported elsewhere.^{11, 12} Procedures were performed only by CREST-certified interventionalists and surgeons.

Outcomes

In CREST, the primary composite endpoint was any stroke, myocardial infarction, or death during the periprocedural period or ipsilateral stroke in follow-up. For the purposes of this analysis, CREST centers were divided into tertiles based on the number of patients enrolled into the study, with Group 1 composed of sites each enrolling <25 patients, Group 2 with sites enrolling 25–51 patients and Group 3 with sites enrolling >51 patients. Baseline demographic information for patients in each group was recorded. The number of interventionalists and surgeons was recorded.

Statistical Analysis

Baseline demographics, comorbidities, and procedural information were summarized with descriptive summary statistics. Differences in periprocedural event rates by center enrollment volume for the primary composite endpoint and its components were compared using logistic regression adjusting for age, sex, and symptomatic status. Comparisons in event rates by center enrollment volume were made separately for each treatment. Tests for linear trend across all three volume groups were conducted to assess the significance of the increase in risk per category of change. Clinically, a hazard ratio between 2–3 was considered to be important to patients and their physicians. Comparisons within site-volume

level by treatment group were then performed and tests for treatment by volume interactions were conducted.

RESULTS

As previously reported,¹⁴ 158 interventionalists and 477 surgeons were credentialed in CREST; 2502 patients were randomized, and there was no difference between CAS and CEA in the estimated 4-year rates of the primary outcome (7.2% and 6.8%, respectively; HR 1.11, 95% CI 0.81–1.51; $p=0.51$).¹¹

Group 1 (853 patients) included 82 sites each enrolling <25 patients; Group 2 (848 patients) included 24 sites enrolling 25–51 patients; Group 3 (801 patients) included 10 sites enrolling >51 patients. Baseline demographic information for each of the three groups is listed in Table 1. Patients at centers with higher enrollment volume tended to be older, more likely male, more likely white and more likely to be symptomatic ($p < 0.005$). There were no other significant differences in baseline risk factors between the groups except for smoking status ($p < 0.0001$) and days from randomization to treatment ($p=0.002$, Table 1). In parallel with patient volumes, the number of surgeons and interventionists increased, with nearly double the number of each in Group 3 compared to Group 1 ($p < 0.001$, Table 1).

Event rates by center enrollment volume, adjusted for age, sex and symptomatic status were compared for CAS (Table 2) and CEA (Table 3) separately. For the CAS group, on average, there was a 24% increase (OR = 1.24; 95% CI: 0.90 – 1.70) in the odds of a primary endpoint per category of patient volume as we contrast the small, medium and large volume groups; however, the increase was not significant. Similar results were found for the MI, and stroke and death endpoints. Within the CEA group, there was a slight reduction in risk (OR=0.97; 95% CI: 0.70 – 1.36) in the odds of a primary endpoint per category of patient volume moving from small to large. There was a reduced risk of MI (OR=0.68; 95% CI: 0.42 – 1.11) and an increase in odds of stroke and death (OR=1.29; 95% CI: 0.81 – 2.07) as you moved from small to large volume, but none of these differences were significant.

Table 4 provides details of event rates for complications of CAS and CEA by site-volume, with adjustment for age, sex and symptomatic status. The safety of CAS and CEA did not vary by site-volume during the periprocedural period as indicated by non-significant odds ratios for each treatment comparison within center enrollment volume level. The overall test for treatment by volume interactions were non-significant for all endpoints (primary endpoint ($p=0.54$), MI ($p=0.34$), or by stroke and death ($p=0.87$)).

DISCUSSION

Complication rates were low in CREST and were not associated with center enrollment volume. Historically, a learning curve has been present with both methods of revascularization.^{1, 4} Outcomes have been shown to be related to both surgeon volume and hospital volume for CEA^{2, 3, 6, 17} and similar data have been reported for CAS.^{7, 8, 18} Our data did not demonstrate an association with outcome and enrollment volume by site of patients entered into CREST, most likely because the interventionalists and surgeons were selected based on demonstration of experience with the procedures and devices as well as

upon event rates within an accepted standard combined with on-going monitoring for complications throughout the study. We suggest that these results underscore the value of rigorous training and credentialing in trials evaluating endovascular devices and surgical procedures. The certification requirements in CREST likely minimized the variability in outcomes due to operator experience.

Our results are similar to those reported in the Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) study where complication rates did not differ by center enrollment rates.¹⁹ In contrast, the results reported in the Stent-Protected Angioplasty versus Endarterectomy (SPACE) study showed an association between complication rate and patient volume for CAS but not for CEA.⁹ Standardization for the interventionalists in SPACE differed from CREST. Interventionalists in SPACE could be credentialed if they had performed 25 stents or angioplasties in any vascular location. For credentialing in CREST, interventionalists had to submit documents for 10–20 carotid stents and then had to participate in a Lead-In registry with up to 20 carotid stents (n= 1565). In addition, 3 stent devices and 5 embolic protection devices (EPD) were approved for use in SPACE.²⁰ Only one CAS system and EPD was used in CREST which helps to avoid confounding due to external factors related to different devices, but limits the generalizability of our results.

There are several limitations to our analysis. We categorized centers into tertiles; however, a ‘low-enrolling site’ in CREST does not equate to a low-volume site since we do not have data regarding the number of patients who underwent revascularization outside CREST at each center. Similarly, because of ongoing entry of new interventionalists and surgeons into CREST, operator experience independent of center enrollment volume cannot be addressed. Overall, event rates in this analysis were similar to the periprocedural rates reported in the CREST primary analysis for CAS and CEA (5.2 and 4.5%, respectively; HR for CAS, 1.18; 95% CI, 0.82– 1.68; P = 0.38); however, in addition to event rates being low, CREST was not powered to detect differences in outcome based on center enrollment volume. Our observations are specific to the CREST trial so these results may not be generalizable and should be interpreted with caution.

Regarding CAS, there is no consensus on the minimum number of CAS procedures required to define safety⁵ nor for maintenance of competency.²¹ Moreover, different specialty societies have different elements which define competency.^{21–23} This issue is further complicated by other factors such as patient comorbidities and hospital volume, which are also associated with safety. CREST included interventionalists and operators from multiple specialties. Our results strongly suggest that careful selection of interventionalists and operators ensures that confounding of results due to experience and device is minimized.

SUMMARY

Complication rates in CREST were not associated with center enrollment volume. Rigorous credentialing requirements may overcome the ‘learning’ curve and provide a more accurate approximation of the safety of revascularization procedures for carotid artery stenosis.

ACKNOWLEDGEMENTS

SOURCES OF FUNDING

The study was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (U01 NS 038384) with supplemental funding from Abbott Vascular, Inc.

REFERENCES

1. Archie JP Jr. Learning curve for carotid endarterectomy. *South Med J*. 1988; 81:707–710. [PubMed: 3375874]
2. Feasby TE, Quan H, Ghali WA. Hospital and surgeon determinants of carotid endarterectomy outcomes. *Arch Neurol*. 2002; 59:1877–1881. [PubMed: 12470174]
3. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the united states. *N Engl J Med*. 2003; 349:2117–2127. [PubMed: 14645640]
4. Verzini F, Cao P, De Rango P, Parlani G, Maselli A, Romano L, et al. Appropriateness of learning curve for carotid artery stenting: An analysis of periprocedural complications. *J Vasc Surg*. 2006; 44:1205–1211. discussion 1211–1202. [PubMed: 17055692]
5. Parlani G, De Rango P, Verzini F, Cieri E, Simonte G, Casalino A, et al. Safety of carotid stenting (CAS) is based on institutional training more than individual experience in large-volume centres. *Eur J Vasc Endovasc Surg*. 2013; 45:424–430. [PubMed: 23481410]
6. Holt PJ, Poloniecki JD, Loftus IM, Thompson MM. Meta-analysis and systematic review of the relationship between hospital volume and outcome following carotid endarterectomy. *Eur J Vasc Endovasc Surg*. 2007; 33:645–651. [PubMed: 17400005]
7. Gray WA, Rosenfield KA, Jaff MR, Chaturvedi S, Peng L, Verta P. Influence of site and operator characteristics on carotid artery stent outcomes: Analysis of the CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) clinical study. *JACC Cardiovasc Interv*. 2011; 4:235–246. [PubMed: 21349464]
8. Staubach S, Hein-Rothweiler R, Hochadel M, Segerer M, Zahn R, Jung J, et al. The role of endovascular expertise in carotid artery stenting: Results from the ALKK-CAS-Registry in 5,535 patients. *Clin Res Cardiol*. 2012; 101:929–937. [PubMed: 22645102]
9. Fiehler J, Jansen O, Berger J, Eckstein HH, Ringleb PA, Stinge R. Differences in complication rates among the centres in the SPACE study. *Neuroradiology*. 2008; 50:1049–1053. [PubMed: 18810400]
10. Calvet D, Mas JL, Algra A, Becquemin JP, Bonati LH, Dobson J, et al. Carotid stenting: Is there an operator effect? A pooled analysis from the carotid stenting trialists' collaboration. *Stroke*. 2014; 45:527–532. [PubMed: 24347422]
11. Brott TG, Hobson RW 2nd, Howard G, Roubin GS, Clark WM, Brooks W, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. *N Engl J Med*. 2010; 363:11–23. [PubMed: 20505173]
12. Sheffet AJ, Roubin G, Howard G, Howard V, Moore W, Meschia JF, et al. Design of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST). *Int J Stroke*. 2010; 5:40–46. [PubMed: 20088993]
13. Hobson RW 2nd, Howard VJ, Roubin GS, Ferguson RD, Brott TG, Howard G, et al. Credentialing of surgeons as interventionalists for carotid artery stenting: Experience from the lead-in phase of CREST. *J Vasc Surg*. 2004; 40:952–957. [PubMed: 15557910]
14. Hopkins LN, Roubin GS, Chakhtoura EY, Gray WA, Ferguson RD, Katzen BT, et al. The Carotid Revascularization Endarterectomy vs. Stenting Trial: Credentialing of interventionalists and final results of lead-in phase. *J Stroke Cerebrovasc Dis*. 2010; 19:153–162. [PubMed: 20189092]
15. Endarterectomy for asymptomatic carotid artery stenosis. Executive committee for the Asymptomatic Carotid Atherosclerosis Study. *Jama*. 1995; 273:1421–1428. [PubMed: 7723155]

16. Moore WS, Vescera CL, Robertson JT, Baker WH, Howard VJ, Toole JF. Selection process for surgeons in the Asymptomatic Carotid Atherosclerosis Study. *Stroke*. 1991; 22:1353–1357. [PubMed: 1750041]
17. Hannan EL, Popp AJ, Tranmer B, Fuestel P, Waldman J, Shah D. Relationship between provider volume and mortality for carotid endarterectomies in New York state. *Stroke*. 1998; 29:2292–2297. [PubMed: 9804636]
18. Nallamothu BK, Gurm HS, Ting HH, Goodney PP, Rogers MA, Curtis JP, et al. Operator experience and carotid stenting outcomes in medicare beneficiaries. *JAMA*. 2011; 306:1338–1343. [PubMed: 21954477]
19. Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. *N Engl J Med*. 2006; 355:1660–1671. [PubMed: 17050890]
20. Ringleb PA, Allenberg J, Bruckmann H, Eckstein HH, Fraedrich G, Hartmann M, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: A randomised non-inferiority trial. *Lancet*. 2006; 368:1239–1247. [PubMed: 17027729]
21. Connors JJ 3rd, Sacks D, Furlan AJ, Selman WR, Russell EJ, Stieg PE, et al. Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: A joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology. *J Vasc Interv Radiol*. 2009; 20:S292–S301. [PubMed: 19560013]
22. Rosenfield K, Babb JD, Cates CU, Cowley MJ, Feldman T, Gallagher A, et al. Clinical competence statement on carotid stenting: Training and credentialing for carotid stenting--multispecialty consensus recommendations: A report of the SCAI/SVMB/SVS writing committee to develop a clinical competence statement on carotid interventions. *J Am Coll Cardiol*. 2005; 45:165–174. [PubMed: 15629399]
23. Bates ER, Babb JD, Casey DE Jr, Cates CU, Duckwiler GR, Feldman TE, et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document on carotid stenting: A report of the American College of Cardiology foundation task force on clinical expert consensus documents (ACCF/SCAI/SVMB/SIR/ASITN clinical expert consensus document committee on carotid stenting). *J Am Coll Cardiol*. 2007; 49:126–170. [PubMed: 17207736]

Table 1

Baseline demographics, clinical characteristics and interventionalist/surgeon information.

Variable	Group 1 <25 patients (n=853 patients)	Group 2 25–51 patients (n=848 patients)	Group 3 >51 patients (N=801 patients)	p-value
Age, yrs, mean (SD)	69.6+8.7	69.6+8.9	67.8+8.9	<0.0001
Male, %	61.3	65.5	68.9	0.005
White race, %	93.9	88.8	97.1	<0.0001
Symptomatic, n (%)	44.7	54.4	59.8	<0.0001
Risk Factor, n (%)				
Hypertension	87.3	84.4	86.0	0.22
Diabetes	33.0	29.2	29.2	0.15
Dyslipidemia	85.9	83.2	83.9	0.28
Prior cardiovascular Disease or CABG	47.1	45.2	42.4	0.17
Current smoker	23.0	24.2	32.0	<0.0001
Days from randomization to treatment, median (IQR)	7 (9)	7 (9)	6 (8)	0.002
Mean number of interventionalists who performed at least 1 procedure per center*	1.3	1.9	2.5	<0.0001
Mean number of surgeons who performed at least 1 procedure per center*	1.8	2.6	3.0	<0.0001

* counted as an interventionalist if performed CAS procedure; counted as surgeon if performed CEA, CABG, coronary artery bypass graft; CAS, carotid angioplasty and stenting; CEA, carotid endarterectomy; IQR, interquartile range.

Table 2

Event rates by center enrollment volume for CAS.

	Group 1 <25 patients No. events/ No. subjects (rate ± SE)	Group 2 25 – 51 patients No. events/ No. subjects (rate ± SE)	Group 3 >51 patients No. events/ No. subjects (rate ± SE)	OR (95% CI) *	p-value
MI (any MI during peri- procedural period) OR (95% CI)	5/429 (1.2±0.5) reference	3/432 (0.7±0.4) 0.62 (0.15 – 2.62)	6/401 (1.5 ± 0.6) 1.53 (0.46 – 5.13)	1.26 (0.65 – 2.45)	0.49 0.44
Stroke and Death Endpoint (any stroke or death within peri- procedural period) OR (95% CI)	18/429 (4.2 ± 1.0) reference	13/432 (3.0 ± 0.8) 0.67 (0.32 – 1.39)	24/401 (6.0 ± 1.2) 1.49 (0.79 – 2.84)	1.25 (0.89 – 1.77)	0.20 0.07
Primary Endpoint (any stroke, MI or death within peri-procedural period) OR (95% CI)	22/429 (5.1 ± 1.1) reference	16/432 (3.7 ± 0.9) 0.68 (0.35 – 1.33)	28/401 (7.0 ± 1.3) 1.47 (0.82 – 2.66)	1.24 (0.90 – 1.70)	0.19 0.06

* OR (95% CI) adjusted for age, sex and symptomatic status;

CAS, carotid artery stent; MI, myocardial infarction; OR, odds ratio; CI, confidence interval

Table 3

Event rates by center enrollment volume for CEA.

	Group 1 <25 patients No. events/ No. subjects (rate ± SE)	Group 2 25 – 51 patients No. events/ No. subjects (rate ± SE)	Group 3 >51 patients No. events/ No. subjects (rate ± SE)	OR (95% CI) [*]	p-value
MI (any MI during peri- procedural period) OR (95% CI)	13/424 (3.1 ± 0.8) reference	9/416 (2.2 ± 0.7) 0.66 (0.28 – 1.58)	6/400 (1.5 ± 0.6) 0.47 (0.17 – 1.27)	0.68 (0.42 – 1.11)	0.12 0.30
Stroke and Death Endpoint (any stroke or death within peri- procedural period) OR (95% CI)	8/424 (1.9 ± 0.7) reference	8/416 (1.9 ± 0.7) 0.92 (0.34 – 2.49)	13/400 (3.3 ± 0.9) 1.59 (0.64 – 3.94)	1.29 (0.81 – 2.07)	0.29 0.41
Primary Endpoint (any stroke, MI or death within peri-procedural period) OR (95% CI)	20/424 (4.7 ± 1.0) reference	17/416 (4.1 ± 1.0) 0.80 (0.41 – 1.83)	19/400 (4.8 ± 1.1) 0.95 (0.49 – 1.83)	0.97 (0.70 – 1.36)	0.87 0.79

^{*} OR (95% CI) adjusted for age, sex and symptomatic status;

CEA, carotid endarterectomy; MI, myocardial infarction; OR, odds ratio; CI, confidence interval

Differences in periprocedural event rates for the primary composite endpoint and its components by volume and treatment group.

Table 4

	CAS #events/#Subjects (rate ± SE)	CEA #events/#Subjects (rate ± SE)	CAS-to- CEA OR (95% CI)*	Treatment by Site-Size Interaction p-value*
MI Endpoint (any MI within peri- procedural period)	Group 1	5/429 (1.2 ± 0.5)	13/424 (3.1 ± 0.8)	0.34
	Group 2	3/432 (0.7 ± 0.4)	9/416 (2.2 ± 0.7)	
	Group 3	6/401 (1.5 ± 0.6)	6/400 (1.5 ± 0.6)	
Stroke and Death Endpoint (any stroke or death within peri- procedural period)	Group 1	18/429 (4.2 ± 1.0)	8/424 (1.9 ± 0.7)	0.87
	Group 2	13/432 (3.0 ± 0.8)	8/416 (1.9 ± 0.7)	
	Group 3	24/401 (6.0 ± 1.2)	13/400 (3.3 ± 0.9)	
Primary Endpoint (any stroke, MI or death within peri- procedural)	Group 1	22/429 (5.1 ± 1.1)	20/424 (4.7 ± 1.0)	0.54
	Group 2	16/432 (3.7 ± 0.9)	17/416 (4.1 ± 1.0)	
	Group 3	28/401 (7.0 ± 1.3)	19/400 (4.8 ± 1.1)	

* adjusted for age, sex and symptomatic status;

CAS, carotid artery stent; CEA, carotid endarterectomy; MI, myocardial infarction; OR, odds ratio; CI, confidence interval